These features have not previously been used or described in the domain of breast radiomics except in Li et al. (2020) and Xie et al. (2019) studies, who used new features to differentiate different subtypes of breast cancer and predict DFS in patients with HER2-positive breast cancer treated with NAC. This evidence concerns the gene ERBB2 and breast carcinoma.